-
Mashup Score: 7
The protocol of a randomised trial is the foundation for study planning, conduct, reporting, and external review. However, trial protocols vary in their completeness and often do not address key elements of design and conduct. The SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) statement was first published in 2013 as guidance to improve the completeness of trial protocols. Periodic updates incorporating the latest evidence and best practices are needed to ensure that the guidance remains relevant to users.
Source: www.thelancet.comCategories: General Medicine NewsTweet
-
Mashup Score: 15Supporting medical science in the USA - 2 day(s) ago
The pursuit of rigorous medical science is not compatible with capitulation to government demands aimed at weaponising and eroding science. On April 14, Edwin R Martin Jr, the Trump-appointed interim US attorney for the District of Columbia, sent a letter to at least one medical journal, CHEST, saying “that more and more journals and publications like CHEST Journal are conceding that they are partisans in various scientific debates”. The letter asked the journal to respond to five questions on topics such as how it handles misinformation and different viewpoints.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Very important editorial in The Lancet today. Please read. Supporting medical science in the USA - The Lancet https://t.co/ADZVR6qRDJ
-
-
Mashup Score: 10Proposed tariffs on pharmaceuticals cause concerns about increased drug prices and drug shortages in the USA - 2 day(s) ago
The USA appeared to move closer to imposing tariffs on pharmaceuticals after filing a federal notice on April 14, 2025, announcing an investigation into whether medicine and active ingredient imports threaten national security.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
News: Proposed tariffs on pharmaceuticals cause concerns about increased drug prices and drug shortages in the USA By Sharmila Devi https://t.co/r3x2EJTWxM
-
-
Mashup Score: 14Supporting medical science in the USA - 5 day(s) ago
The pursuit of rigorous medical science is not compatible with capitulation to government demands aimed at weaponising and eroding science. On April 14, Edwin R Martin Jr, the Trump-appointed interim US attorney for the District of Columbia, sent a letter to at least one medical journal, CHEST, saying “that more and more journals and publications like CHEST Journal are conceding that they are partisans in various scientific debates”. The letter asked the journal to respond to five questions on topics such as how it handles misinformation and different viewpoints.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Very important editorial in The Lancet today. Please read. Supporting medical science in the USA - The Lancet https://t.co/ADZVR6qRDJ
-
-
Mashup Score: 29
The modified FLOT/TFOX regimen significantly improved progression-free survival, overall survival, and objective response rate compared with FOLFOX in previously untreated patients with advanced HER2-negative gastric and gastro-oesophageal junction adenocarcinoma. The modified FLOT/TFOX regimen might represent a new first-line treatment option for patients eligible for this docetaxel triplet chemotherapy.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Online: PRODIGE 51-FFCD-GASTFOX , a phase 3 trial assessing a modified FLOT regimen (TFOX) vs FOLFOX as first-line treatment for patients with HER2-negative #gastriccancer 📰Article: https://t.co/QQxSe5baoz 📝Linked comment: https://t.co/z1Xyabqv0W https://t.co/YSUrHOMPsm
-
-
Mashup Score: 95
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended follow-up is required. The results of the present trial could be used for patient counselling and shared decision making.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial https://t.co/7pQ9KeJYnQ https://t.co/9t5Yix6DfU
-
-
Mashup Score: 95
Overall survival after active surveillance for oesophageal cancer was non-inferior compared with standard surgery after 2 years. For the long-term efficacy of active surveillance, extended follow-up is required. The results of the present trial could be used for patient counselling and shared decision making.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
New research: Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for #oesophagealcancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial https://t.co/7pQ9KeJYnQ https://t.co/9t5Yix6DfU
-
-
Mashup Score: 10
The benefit-risk assessment of cancer treatments usually focuses on traditional clinical and disease outcomes, such as overall survival, progression-free survival, and tumour response, balanced against clinician-reported adverse events. Patient-reported outcomes (PROs) measuring symptoms, functioning, and other health-related quality of life (HRQOL) impacts can be used to ensure that a drug’s effect on symptoms and functioning are quantified and evaluated as part of cancer clinical research and drug development.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
Online first: highlights from an @EMA_News @EORTC workshop: using patient-reported outcomes and #QoL data in regulatory decisions 📰Perspective: https://t.co/13VdDB3e5u 📝Comment: https://t.co/sZmOOFSwHf
-
-
Mashup Score: 1
Talazoparib plus enzalutamide prolonged time to definitive deterioration in GHS/QoL versus placebo plus enzalutamide. Together with clinical efficacy and safety data, these results inform the risk-benefit assessment of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer in TALAPRO-2.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
And a related article here: https://t.co/Yy5LaPtbXF
-
-
Mashup Score: 8
The demonstrated delays in definitive deterioration in GHS/QoL, urinary symptoms, and other functioning and symptom scales with talazoparib plus enzalutamide compared with placebo plus enzalutamide in patients with HRR-deficient metastatic castration-resistant prostate cancer provide insight that might inform clinical decisions for these patients.
Source: www.thelancet.comCategories: General Medicine NewsTweet-
See here for the article: https://t.co/yGjL9xbTsD https://t.co/vTaqLKWhoW
-
RT @TheLancet: SPIRIT 2025 statement: updated guideline for protocols of randomised trials 🔗 https://t.co/weOfoDwQDE https://t.co/dxfbOjHQ…